2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Transplantation, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

1862 First-line polatuzumab vedotin in double-expressor DLBCL: An unanchored population-adjusted indirect comparison with tucidinostat plus R-CHOP and R-CHOP in the DEB trial.

Zhihua Yao, Jiuyang Zhang, MD2, quande Lin, PhD3, Jianwei Du4, Shuna Yao5, Lihua Dong6, Xiaoqiang Zhao, N/A7, Haiping Yang, MD8, Jinxiao Yao9, chao Li, N/A10, Qiuhong Wang11, Yifei Chen, MD12, Fuli Qin13, Xiaoyan Lin14, Xiaojuan Liu15, Wenyong Li16, Ping Wang17, Xiaojuan Zhang18, shuhao mei19, Zhihui Li, MD20, Yanrong Shi21, Cailing Wang22, Zhengrong Liu23, Genjie Wang, N/A24, Ning Hu25, Shen He26, Hongyan Ma27, Xueli Jiao, MD28, Xingchen Liu, MD29, Qianying Pan, MD30, Qing Zhang, MD31, Jingyi Yang, MD32, Hao Guo, MD, PhD33, Fenghua Gao34, Xinyang Zhao, PhD35, Keshu Zhou, PhD36
1 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
2 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
3 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
4 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
5 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
6 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
7 ?The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
8 ?The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
9 The Second People's Hospital of Nanyang City, Nanyang, China
10 Nanyang Central Hospital, Nayang, China
11 Jiyuan People's Hospital, JIyuan, China
12 Jiangdu People's Hospital Affiliated to Yangzhou University, Yangzhou, China
13 Zheng zhou Central Hospital, Zhengzhou, China
14 Puyang Oilfield General Hospital, Puyang, China
15 Jiaozuo Second People’s Hospital, Jiaozuo, China
16 Jiaozuo People's Hospital, Jiaozuo, China
17 Zhumadian Center Hospital?, Zhumadian, China
18 The Fifth Clinical Medical College of Henan University of Chinese Medicine ( Zhengzhou People's Hospital ), Zhengzhou, China
19 Xuchang Central Hospital, Xuchang, China
20 Xinxiang Central Hospital,, Xinxiang, China
21 Pingmei Shenma Medical Group General Hospital?, Pingdingshan, China
22 Anyang Tumor Hospital, Anyang, China
23 Anyang People's Hospital, Anyang, China
24 Shangqiu First People’s Hospital, Shangqiu, China
25 HuaiHe Hospital of Henan University, Kaifeng, China
26 Department of Hematology, Kaifeng Center Hospital, Kaifeng, China
27 The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
28 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
29 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
30 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
31 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
32 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
33 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
34 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
35 Kansas University Medical Center, Kansas, United States
36 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

Background

Double-expressor lymphoma (DEL; MYC and BCL2 co-overexpression) carries poor prognosis with R-CHOP. The randomized phase 3 DEB trial demonstrated improved event-free survival and complete response (CR) rates with tucidinostat plus R-CHOP compared with placebo plus R-CHOP in previously untreated DEL. However, its comparative effectiveness versus first-line polatuzumab-based therapy remains unknown. We conducted an unanchored matching-adjusted indirect comparison (MAIC) of a prospective multicenter real-world (RW) cohort of patients with DEL treated with first-line polatuzumab-based therapy versus both arms of the DEB trial, focusing on end-of-treatment CR.

Methods

RW cohort included 126 DEL patients with first-line pola-based therapy (98 with complete  covariates). Double-/triple-hit lymphoma (DH/TH) was prospectively excluded to align with the DEB definition regarding DH/TH status and reduce cross-study genetic heterogeneity. Unanchored MAIC (entropy balancing) matched to the DEB ITT pooled baseline proportions across six covariates: age >60, female sex, IPI 3–5, stage III–IV, elevated LDH, and GCB. The primary outcome was end-of-treatment CR, with ORR evaluated as a secondary response outcome. The weighted RW cohort was compared separately with the DEB placebo plus R-CHOP arm (n=212) and tucidinostat plus R-CHOP arm(n=211). a mature-cohort analysis avoiding immortal-time bias, standard Pola-R-CHP restriction, center-clustered bootstrap CIs, and multiple imputation. Weight distribution, effective sample size, and post-weighting covariate balance were assessed.

Results

After weighting, all six covariates were balanced to pooled DEB ITT target proportions. The effective sample size was 66. The weighted ORR and CR rates in the RW Pola-treated DEL cohort were 94.9% and 76.4%, respectively; the center-clustered bootstrap 95% CI for CR was 67.5%–84.8%.

Compared with the DEB placebo plus R-CHOP arm, which had an ORR of 75.0% and a CR rate of 61.8%, Pola-based therapy was associated with an ORR risk difference of +19.9 percentage points (95% CI, 11.6–28.2; P<0.0001) and a CR risk difference of +14.6 percentage points (95% CI, 1.5–27.7; P=0.029).

Compared with tucidinostat plus R-CHOP, which had an ORR of 84.4% and a CR rate of 73.0%, the ORR risk difference was +10.5 percentage points (95% CI, 2.9–18.2; P=0.007), whereas the CR risk difference was +3.4 percentage points (95% CI, −9.5 to 16.2; P=0.60). The CR estimate was imprecise and established neither superiority nor non-inferiority.

In sensitivity analyses, the crude CR rate was 80.0% among patients who completed at least six cycles and 50.0% among those who received fewer than six cycles. A completer-only analysis yielded a weighted CR rate of 85.5% but was susceptible to treatment-dependent selection and immortal-time bias. In contrast, an immortal-time-avoiding mature-cohort analysis included all patients who, by the data cutoff, had sufficient potential follow-up to complete six cycles and undergo end-of-treatment assessment, irrespective of actual treatment completion. Early progression, death, treatment discontinuation, or treatment switch before end-of-treatment assessment was classified as non-CR. The weighted CR rate in this analysis was 76.7%, similar to the primary estimate of 76.4%, and the higher estimate observed in treatment completers was not reproduced.

Results were also consistent in the standard Pola-R-CHP subset (n=56; ESS=53.4), in which the weighted CR rate was 77.6%. The CR risk difference versus placebo plus R-CHOP was +15.8 percentage points (95% CI, 1.3–30.3; P=0.033). Multiple imputation of missing covariates yielded a weighted CR rate of 75.4%, approximately 1 percentage point lower than the complete-case estimate, suggesting limited sensitivity of the CR estimate to missing baseline covariates.

Conclusions

In double-expressor DLBCL, first-line Pola-based therapy was associated with a higher population-adjusted CR rate than the DEB placebo plus R-CHOP arm, while showing a small, imprecisely estimated CR difference compared with tucidinostat plus R-CHOP. These findings were consistent across sensitivity analyses (including standard Pola-R-CHP, an immortal-time-avoiding mature cohort, and multiple imputation) and after excluding DH/TH to reduce heterogeneity. Given the unanchored, cross-study design, these exploratory findings require confirmation in prospective, head-to-head trials.

Zhihua Yao: No relevant conflicts of interest to declare.